证券代码：002020 证券简称：京新药业 公告编号：2023040 浙江京新药业股份有限公司 关于地达西尼胶囊获批上市的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江京新药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的 1 类创新药"地达西尼胶囊"的《药品注册证书》，批准文号 为国药准字 H20230030。现将相关情况公告如下： 一、药品基本情况 产品名称：地达西尼胶囊 剂型：胶囊剂 规格：2.5mg 注册分类：化学药品 1 类 申请事项：药品注册（境内生产） 申请人：浙江京新药业股份有限公司 适应症：适用于失眠患者的短期治疗 二、药品研发及其他相关情况 地达西尼是治疗失眠的 1 类小分子新药，为γ-氨基丁酸 A 型（GABAA）受体 的部分正向别构调节剂，通过部分激活 GABAA 受体，产生促进睡眠的作用。与传 统的失眠药物相比，地达西尼具有独特的代谢通路，使药物相互作用可能性显著 降低，方便有基础疾病的失眠患者合并用药，在运动障碍、后遗效应、耐受性、 乙醇相互作用、身体依赖性、记忆力损伤等不良反应方面，也具有明显的优 ...

Group 1: Company Overview - In Q3 2023, the company achieved a revenue of 989 million CNY, with a cumulative revenue of 2.926 billion CNY for the first three quarters, representing a year-on-year growth of 4.48% [3] - The net profit attributable to shareholders in Q3 2023 was 157 million CNY, with a cumulative net profit of 473 million CNY for the first three quarters, showing a year-on-year increase of 0.18% [3] Group 2: Product Development and Sales Strategy - The approval expectation and sales strategy for the drug Didasyn were discussed, with the NDA submitted in April 2022 and currently under technical review [3] - The company is preparing for the commercialization of Didasyn by leveraging its established sales team and academic promotion to gain recognition from experts and doctors [4] Group 3: Sales Adjustments and Market Response - The company has restructured its sales framework, merging divisions to establish two main business units: hospitals and retail, in response to market changes [4] - Despite external challenges, the sales of finished pharmaceutical products have gradually returned to normal in the latter half of the year, indicating a positive trend [4] Group 4: Future Development Plans - The company plans to develop its traditional Chinese medicine (TCM) sector independently, addressing capacity bottlenecks through the launch of a production base in Inner Mongolia [4] - The new Shandong raw material drug base will enhance production efficiency by separating intermediate production from API, addressing existing capacity constraints and expanding product range [4]

Revenue and Profit - The company's revenue for Q3 2023 was ¥988,985,036.16, representing a 6.65% increase year-over-year[6] - Net profit attributable to shareholders decreased by 10.31% to ¥156,699,380.93 in Q3 2023[6] - The net profit excluding non-recurring gains and losses was ¥146,390,169.67, down 14.68% compared to the same period last year[6] - Total operating revenue for the current period reached ¥2,925,537,429.00, an increase of 4.48% from ¥2,800,058,651.27 in the previous period[29] - Net profit for the current period was ¥475,952,284.31, slightly up from ¥475,470,952.50 in the previous period, reflecting a growth of 0.10%[29] - The total comprehensive income attributable to the parent company's owners was CNY 473,291,140.84, compared to CNY 472,409,977.97 in the previous period, showing a slight increase[33] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date period decreased by 26.56% to ¥500,457,167.03[6] - Cash flow from operating activities generated a net amount of ¥500,457,167.03, down from ¥681,416,066.30 in the previous period[30] - Cash flow from investing activities resulted in a net outflow of ¥600,246,432.81, slightly improved from a net outflow of ¥617,421,539.09 in the previous period[30] - Cash and cash equivalents were reported at CNY 1,243,076,314.62, down from CNY 1,548,475,399.92, indicating a decrease of approximately 19.7%[22] - Cash and cash equivalents at the end of the period totaled ¥1,205,169,946.47, down from ¥1,401,844,562.75 at the end of the previous period[30] Assets and Liabilities - Total assets increased by 3.50% to ¥7,620,113,019.74 compared to the end of the previous year[6] - The company's current assets decreased to CNY 2,733,581,937.57 from CNY 3,281,165,784.46, representing a decline of about 16.7%[22] - The total liabilities increased to CNY 2,233,850,745.76 from CNY 2,190,585,660.02, marking an increase of about 2.0%[27] - The company's equity attributable to shareholders rose by 4.18% to ¥5,361,097,357.80[6] - The company's equity attributable to shareholders rose to CNY 5,361,097,357.80 from CNY 5,146,123,375.50, showing an increase of approximately 4.2%[27] - The total non-current assets increased to CNY 4,886,531,082.17 from CNY 4,081,390,078.48, representing a growth of approximately 19.8%[22] Expenses and Costs - Total operating costs increased to ¥2,433,056,491.69, up 5.77% from ¥2,300,367,857.99 in the previous period[29] - Research and development expenses rose to ¥259,456,442.07, an increase of 5.67% compared to ¥246,403,668.53 in the previous period[29] - The company reported a decrease in sales expenses to ¥605,886,403.51, down 10.77% from ¥679,200,078.77 in the previous period[29] - The company's financial expenses showed improvement, with a net income of -¥38,235,729.66 compared to -¥59,376,378.44 in the previous period[29] Other Financial Metrics - The weighted average return on equity decreased by 0.41 percentage points to 2.97% for Q3 2023[6] - The company's total liabilities to equity ratio stands at approximately 41.5%, indicating a stable leverage position[27] - The basic and diluted earnings per share remained stable at CNY 0.55[33] - The net profit attributable to minority shareholders was CNY 3,342,046.57, compared to CNY 3,737,377.35 in the previous period, indicating a decrease[33]

Group 1: Strategic Focus - The company will continue to focus on innovative drugs in the fields of mental health and cardiovascular diseases, specifically targeting conditions such as schizophrenia, Parkinson's disease, depression, and epilepsy [2][3] - The integration of raw materials and formulations is a key strategic direction, with a focus on both self-research and external introduction of new products [2][3] Group 2: Production and Capacity Expansion - The company has over 30 years of experience in the intermediate and raw material pharmaceutical industry, supporting its ability to integrate raw materials and formulations effectively [3] - Recent capacity expansions are aimed at overcoming production bottlenecks across different business segments, with a balanced approach to investment and returns [3] Group 3: Sales and Market Adaptation - A restructuring of the sales organization has been implemented to better align with market trends and the company's business characteristics, which may temporarily impact performance but is expected to lay a foundation for sustainable growth [3] - Sales have shown signs of recovery and are trending positively following the adjustments made earlier in the year [3]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"）近日接到控股股东吕钢先 生的函告，获悉吕钢先生所持有本公司的部分股份办理了质押解除，股份质押情 况发生变动。具体事项如下： 二、股东股份累计质押的情况 证券代码：002020 证券简称：京新药业 公告编号：2023038 浙江京新药业股份有限公司 关于控股股东股份质押解除的公告 三、其他说明 一、股东本次解除股份质押的基本情况 股东名 称 是否为控股 股东或第一 大股东及其 一致行动人 本次解除质 押股份数量 （股） 占其所 持股份 比例 占公司 总股本 比例 起始日 解除日期 质权人 吕钢 是 16,800,000 9.40% 1.95% 2020-06-03 2023-10-10 中国工商银行 股份有限公司 新昌支行 截至本公告披露日，公司控股股东及其一致行动人的股份质押事项对公司生 产经营、公司治理等未产生实质性影响，也不涉及业绩补偿义务，不存在平仓风 险。公司将持续关注其质押变动情况及风险，并及时进行披露。敬请投资者注意 风险。 四、备查文件 中国证券登记结算有 ...

上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2023 年第一次临时股东大会的 法律意见书 上海市锦天城律师事务所 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2023 年第一次临时股东大会的 法律意见书 致：浙江京新药业股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江京新药业股份有限公 司（以下简称"公司"或"京新药业"）委托，就公司召开 2023 年第一次临时股东 大会（以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》 （以下简称《公司法》）、《上市公司股东大会规则》等法律、法规、规章和其他 规范性文件以及《浙江京新药业股份有限公司章程》（以下简称《公司章程》）的 有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤 ...

证券代码：002020 证券简称：京新药业 公告编号：2023037 浙江京新药业股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 1、本次股东大会无否决提案的情况； 2、本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开情况 1、本次股东大会的召开时间 现场会议时间：2023 年 9 月 1 日 14:30 起。 网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为 2023 年 9 月 1 日 9:15—9:25,9:30—11:30 和 13:00—15:00；通过深圳证券交易所 互联网投票系统进行网络投票的具体时间为 2023 年 9 月 1 日 9:15 至 15:00 的 任意时间。 2、现场会议地点：浙江省新昌县羽林街道新昌大道东路 800 号本公司行政 楼一楼会议室。 3、会议召开方式：本次会议采取现场投票与网络投票相结合的方式。本 次股东大会通过深圳证券交易所交易系统和互联网投票系统向公司股东提供网 络形式的投票平台，股东可以在网络投票时间内通过上述系统行使表决 ...

股票代码：002020 股票简称：京新药业 浙江京新药业股份有限公司投资者关系活动记录表 编号：2023-006 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他 （请文字说明其他活动内容） | --- | |------------------------------------------------------------------| | 兴业证券邹文凯；西南证券杜向阳、刘潇；东方证券易丹阳、王光宇； | | 博润投资陈玉亮；明河投资张桥石；开源证券刘艺；宁银理财徐厚犇； | | 圆信永丰基金方瑾、田玉铎；安信基金池陈森、孔令琦、孙凌昊；东方 | | 基金王然、王芳玲；华泰证券孙可嘉、许泽昊、李奕玮；东证资管徐宏； | | 青榕资管唐明；富安达基金许睿、李飞；北京凯思博投资陈茜茜；北京 | | 橡果资管魏鑫；上海紫阁投资邱诗；润达安盛胡建东；中邮创业基金王 | | 霞；宁波市浪石投资贺建忠、黄朝豪；华夏久盈资管张伟光；深圳凯丰 | | 投资裴彦春、薛良辰；中国人寿赵文龙；大成基金阳洪宇；广东正圆私 | | 募基金熊小铭、王伟平； ...

Dividend and Shareholder Information - The company plans not to distribute cash dividends or bonus shares for the first half of 2023[4] - The company has not implemented any share buyback or repurchase plans during the reporting period[83] - The company paid out 258,308,742.00 CNY in dividends during the first half of 2023, consistent with the previous year[161] Employee Stock Ownership - The employee stock ownership plan includes 235 employees holding a total of 5,267,045 shares, representing 0.61% of the company's total equity[5] - The company has implemented three employee stock ownership plans since 2019, with the first plan involving 109 participants and an initial fund size of CNY 29.54 million[10] - The company’s employee stock ownership plans have seen a reduction in participants, with 85 remaining in the first plan after the lock-up period expired[10] - The company’s stock ownership among key personnel showed a slight decrease, with Lü Gang holding 269,978 shares at the end of the reporting period, down from 280,618 shares[9] Environmental Compliance and Initiatives - The company reported a total of 1.75 tons of COD emissions, which is below the regulatory limit of 500 mg/l, indicating compliance with environmental standards[19] - The company has obtained pollution discharge permits for its subsidiaries, with the latest permit valid until October 27, 2027[18] - The company’s total emissions of ammonia nitrogen were 0.175 tons, also within the regulatory limit of 35 mg/l[19] - The company has committed to strict adherence to environmental protection laws and regulations, emphasizing its responsibility towards sustainable development[17] - The company has invested CNY 30.9476 million in environmental governance and protection during the reporting period[28] - The company has paid CNY 195,200 in environmental protection tax during the reporting period[28] - The wastewater treatment capacity of the company is 1,600 tons per day, utilizing a multi-stage treatment process to ensure compliance with discharge standards[23] - The company operates two RTO incineration units with a processing capacity of 30,000 m³/h each, ensuring stable operation and compliance with emission standards[23] - The company has established emergency response plans for environmental incidents, with updates filed with local environmental authorities[27] - The company has implemented strict waste classification and disposal measures, ensuring compliance with environmental regulations[24] - The company has no administrative penalties related to environmental issues during the reporting period[35] Financial Performance - Total operating revenue for the first half of 2023 reached ¥1,936,552,392.84, an increase of 3.6% compared to ¥1,872,767,602.14 in the same period of 2022[143] - Net profit for the first half of 2023 was ¥318,447,172.45, compared to ¥299,337,836.21 in the first half of 2022, representing a growth of 6.4%[146] - The total comprehensive income for the first half of 2023 was CNY 319,022,158.84, compared to CNY 299,704,014.79 in the previous year, reflecting a growth of 6.4%[149] - The company’s operating revenue for the reporting period was ¥1,936,552,392.84, representing a 3.41% increase compared to ¥1,872,767,602.14 in the same period last year[170] - The net profit attributable to shareholders of the listed company was ¥315,924,154.48, up 6.35% from ¥297,050,062.50 in the previous year[170] Assets and Liabilities - As of June 30, 2023, total assets amounted to CNY 7,560,806,930.80, an increase from CNY 7,362,555,862.94 on January 1, 2023, representing a growth of approximately 2.7%[134] - Total liabilities increased to CNY 2,330,475,874.12 from CNY 2,190,585,660.02, representing an increase of about 6.4%[137] - The company's equity increased to CNY 5,230,331,056.68 from CNY 5,171,970,202.92, reflecting a growth of approximately 1.1%[137] - The total cash and cash equivalents at the end of the first half of 2023 were CNY 1,371,385,118.38, slightly down from CNY 1,346,106,523.36 at the end of the first half of 2022[157] Research and Development - Research and development expenses were ¥171,121,111.71, slightly increasing from ¥170,157,604.98, indicating a focus on innovation[146] - Research and development expenses for the first half of 2023 were CNY 85,426,172.85, down from CNY 102,972,513.84 in the previous year, indicating a focus on cost management[150] - The company has over 10 innovative drug projects in progress, focusing on clinical value and differentiated layout[194] - The company has been recognized as a "National Technology Innovation Demonstration Enterprise" and has multiple research platforms across different locations[195] Market Position and Product Development - The company is recognized as a national key high-tech enterprise, certified by GMP and FDA, focusing on the research, production, and sales of various pharmaceutical products[179] - The company’s product structure continues to optimize, with stable growth in the profitability of its main business[180] - Key products include cardiovascular drugs such as Rosuvastatin and Simvastatin, and CNS drugs like Levetiracetam and Paroxetine, which are leading in the national hospital market[192] - The company has established a complete pharmaceutical industry chain from raw materials to finished products, enhancing cost advantages and market competitiveness[195] - The company aims to become a leader in the CNS and cardiovascular fields, continuously enhancing its product strength and market position[192] Shareholder Structure - The total number of shares is 861,029,140, with 23.77% being restricted shares and 76.23% being unrestricted shares[80] - The largest shareholder, Lü Gang, holds 20.77% of the shares, totaling 178,796,755, with 134,097,566 shares under lock-up[84] - The company has a total of 25,473 shareholders, with significant shareholders holding more than 5% of the shares[84] - The report indicates that there are no significant changes in the number of shares held by major shareholders during the reporting period[84] Corporate Governance - The company has no significant litigation or arbitration matters during the reporting period[50] - The company has not engaged in any major related party transactions during the reporting period[53] - The company has no significant contracts or leasing matters that impacted profits by more than 10% during the reporting period[65] - The financial report indicates that the company is committed to maintaining transparency and accuracy in its financial disclosures[110]

证券代码：002020 证券简称：京新药业 公告编号：2023035 浙江京新药业股份有限公司 1 | 购 8,055,846 股；发起人自然人股东吕钢认 | | 浙江利丰投资有限公司 805.5846 | 16.08% | | --- | --- | --- | --- | | 购 11,272,500 股，吕岳英认购 | 8,047,723 | 吕岳英 804.7723 | 16.063% | | 股，王光强认购 1,520,894 股，张丽娃认购 | | 王光强 152.0894 | 3.036% | | 1,431,429 股，吴政杰认购 1,431,429 | 股， | 张丽娃 143.1429 | 2.857% | | 杨钰菲认购 1,002,000 股，王能能认购 | | 吴政杰 143.1429 | 2.857% | | 894,644 股，林军认购 894,644 | 股，田庚元 | 中国科学院上海有机化 112.725 | 2.25% | | 认购 483,106 股。 | | | | | | | 学研究所 | | | | | 杨钰菲 100.20 | 2.00% | | | | 中国医学 ...